Le Lézard
Classified in: Health
Subjects: TDS, FVT

Medeor Therapeutics to Present at Cowen Health Care Conference

SAN MATEO, Calif., March 8, 2018 /PRNewswire/ -- Medeor Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies, today announced that its President and Chief Executive Officer, Dr. Steven R. Deitcher, will present on Wednesday, March 14th at 1:00 p.m. EST at the Cowen and Company 38th annual Health Care Conference in Boston.

About Medeor Therapeutics, Inc.
Medeor Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients as well as non-transplant indications. Medeor's series of product candidates each comprise a unique composition of different types of hematopoietic donor-derived cells, initially based on breakthrough technologies discovered at Stanford University and exclusively licensed by Medeor. These product candidates are designed to produce mixed chimerism, the co-existence of both recipient and donor blood and immune cells in the recipient. For organ transplant recipients, mixed chimerism is intended to allow these patients to achieve donor-specific immune tolerance, prevent transplant organ loss, reduce or eliminate chronic immunosuppressive drug therapy, and thereby improve patient outcomes. For more information, visit www.medeortherapeutics.com.


Matthew Plunkett, Ph.D.
Chief Financial and Business Officer


SOURCE Medeor Therapeutics, Inc.

These press releases may also interest you

at 12:30
9:30 a.m. PT ? Luna DNA, the first community owned genomic and medical research database, today announced the addition of three new members to its leadership team. The key hires in the VP of marketing and VP of business strategy and operation roles...

at 12:18
Riverchase Dermatology and Cosmetic Surgery is pleased to announce the newest member of their team, Scott Deckelbaum, D.O., FAAD, FAOCD. Dr. Deckelbaum begins with Riverchase Dermatology on Monday, March 19th and is currently accepting new patients...

at 12:11
Dr. Sheffield's Certified Natural Toothpaste adds Activated Charcoal to its time-tested, fluoride-free lineup, joining Extra Whitening, Natural Wintergreen, Natural Peppermint and Sensitive Care varieties. Made with natural ingredients, Activated...

at 12:00
Cain A. Hayes, president and chief operating officer of the Health Business for Blue Cross and Blue Shield of Minnesota (Blue Cross), has been named by Savoy Magazine as one of 2018's Most Influential Blacks in Corporate America. The African-American...

at 12:00
Scientists at the Benaroya Research Institute at Virginia Mason (BRI) have made a discovery that opens the door to a potentially game-changing way to stop breast cancer tumors from growing and spreading. The researchers ? Emma L. Kuan, PhD, and...

at 11:54
Richards Packaging Income Fund (the "Fund") announced today its cash distribution for the month ended March 31, 2018 of Cdn$0.11 per unit.  This distribution will be to unitholders of record at the close of business on March 30, 2018 and will be...

News published on 8 march 2018 at 16:30 and distributed by: